Ascentage Pharma Clears China IND for BTK Degrader APG-3288, Expanding Global Clinical Pipeline
Event summary
- Ascentage Pharma's BTK degrader APG-3288 received IND clearance from China's CDE on February 5, 2026, following U.S. FDA clearance.
- The company will initiate a multicenter, open-label Phase I study in patients with relapsed/refractory hematologic malignancies.
- APG-3288 uses PROTAC technology to degrade BTK, addressing resistance issues common with existing BTK inhibitors.
- Ascentage Pharma has two approved products in China: Olverembatinib and Lisaftoclax, both targeting hematologic malignancies.
The big picture
Ascentage Pharma's IND clearance for APG-3288 in China marks a strategic milestone in its global expansion, following a similar clearance in the U.S. This dual regulatory approval underscores the company's growing capabilities in targeted protein degradation, a field critical for overcoming resistance in hematologic malignancies. The clearance also strengthens Ascentage Pharma's position in the competitive landscape of BTK-targeted therapies, where resistance remains a significant unmet need.
What we're watching
- Clinical Development Pace
- How quickly Ascentage Pharma advances APG-3288 through Phase I trials in China and the U.S., and whether it meets or exceeds projected timelines.
- Combination Therapy Potential
- Whether APG-3288 can be effectively combined with other assets in Ascentage Pharma's pipeline, particularly Olverembatinib and Lisaftoclax.
- Regulatory Synchronicity
- The alignment of regulatory approvals between China and the U.S., and how this impacts the global development strategy for APG-3288.
Related topics